Lexicon Genetics gets U.K. approval to test small-molecule drug

08/1/2006 | Houston Chronicle (tiered subscription model)

Lexicon Genetics has the green light from British authorities to begin the first human trial of its drug to treat cognitive disorders such as Alzheimer's disease. The Texas firm currently is working with 300,000 mice and embryonic stem cells to block genes that may be associated with human diseases, and the upcoming trials will mark the company's entrance into the independent development of drugs.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA